骨髓活检对GALLIUM和GOYA研究中接受免疫化疗的淋巴瘤患者疗效评估的影响
该研究回顾性分析GALLIUM和GOYA试验中接受免疫化疗的初治滤泡性淋巴瘤(FL)和弥漫大B细胞淋巴瘤(DLBCL)患者,评估治疗后骨髓活检(BMB)组织学对确认完全缓解(CR)的影响。结果显示,在诱导结束(EOI)时CT判定CR的患者中,GALLIUM和GOYA分别有2.8%和4.1%因BMB改变疗效评估;应用Lugano 2014标准时,FL和DLBCL分别有4.7%和7.1%因重复BMB改变评估。提示诱导后BMB对影像学(CT)定义的缓解影响极小;骨髓评估对FL的疗效评估似乎价值不大,但对DLBCL可能仍有意义。
要点
- GALLIUM和GOYA中,EOI时CT判定CR者分别有2.8%和4.1%因BMB改变缓解。
- 应用Lugano 2014标准,FL和DLBCL分别有4.7%和7.1%因重复BMB改变评估。
- 诱导后BMB对CT定义的缓解影响极小;对FL价值似乎不大,DLBCL可能仍有意义。
核心结论
- 诱导后BMB组织学对FL和DLBCL患者CT定义的缓解影响极小。
- 应用Lugano 2014标准时,骨髓评估对FL的疗效评估似乎价值不大,但对DLBCL可能仍有意义。
研究设计与样本
- 回顾性评估GALLIUM(NCT01332968)和GOYA(NCT01287741)两项3期试验中接受免疫化疗的初治FL和DLBCL患者。
- 所有患者均进行基线BMB;对诱导结束(EOI)时CT判定CR且基线BMB阳性的患者重复BMB以确认缓解。
- 部分患者还使用正电子发射断层成像评估EOI缓解(Lugano 2014标准)。
主要发现
- GALLIUM和GOYA中,EOI时CT判定CR的患者分别有2.8%和4.1%因BMB改变缓解评估。
- 应用Lugano 2014标准时,GALLIUM中4.7%的FL患者和GOYA中7.1%的DLBCL患者因重复BMB结果改变缓解评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients with previously untreated follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 3 Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM; NCT01332968) and A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA; NCT01287741) trials, respectively. Baseline BMB was performed in all patients, with repeat BMBs in patients with a CR by computed tomography (CT) at end of induction (EOI) and a positive BMB at baseline, to confirm response. Positron emission tomography imaging was also used in some patients to assess EOI response (Lugano 2014 criteria). Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. In GALLIUM and GOYA, respectively, 4.7% of FL patients and 7.1% of DLBCL patients had a repeat BMB result that altered response assessment when applying Lugano 2014 criteria, indicating that bone marrow evaluation appears to add little value to response assessment in FL; however, its evaluation may still have merit in DLBCL.
引用
- Rutherford SC, Herold M, Hiddemann W, et al. Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. Blood Adv. 2020. PMID: 32298429. doi:10.1182/bloodadvances.2019001261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。